Clinical Investigation of Erlotinib as an HCV Entry Inhibitor

Status Not yet recruiting

Clinical Trial Summary

Chronic Hepatitis C Virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma world-wide. Current combination therapy of pegylated interferon-alfa, ribavirin and protease inhibitors is limited by resistance and substantial side effects.

The investigators identified epidermal growth factor receptor (EGFR) as host factor for HCV infection. Inhibition of kinase function of EGFR by approved inhibitor Erlotinib (TarcevaTM) broadly inhibits HCV infection of all major genotypes including viral escape variants resistant to host immune responses.

Completed preclinical proof-of-concept studies in HCV cell culture and animal model systems demonstrate that inhibition of EGFR function by Erlotinib constitutes a novel antiviral approach for prevention and treatment of HCV infection (European patent application EP 08 305 604.4, Filing date: September 26, 2008; Inserm, Paris, France and Lupberger et al. Nature Medicine 2011).

Since Erlotinib (TarcevaTM) is an established approved drug for cancer treatment and has a well characterized safety profile in humans, the aim of the study is to investigate the safety, efficacy and pharmacokinetics of Erlotinib, a first-in-class entry inhibitor, for treatment of HCV infection in a randomized placebo-controlled double blind clinical trial in patients chronically infected with HCV. Following completion, this trial will set the stage for a further investigation of entry inhibitors as antivirals in combination with standard of care or direct antivirals such as HCV protease inhibitors. Thus, this randomized clinical trial will be an important step in the development of novel urgently needed antiviral therapies overcoming resistance.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01835938
Study type	Interventional
Source	University Hospital, Strasbourg, France
Contact	Pr. Michel Doffoel, MD, PhD
Phone	03 69 55 04 82
Email	michel.doffoel@chru-strasbourg.fr
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	May 2013
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02219503` - A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis	Phase 3
Completed	`NCT02216422` - A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection	Phase 3
Completed	`NCT01700179` - Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants	Phase 1
Completed	`NCT02486406` - A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects	Phase 2/Phase 3
Completed	`NCT01704755` - A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis	Phase 3
Completed	`NCT01225380` - A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C	Phase 2
Completed	`NCT01221298` - A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)	Phase 2
Completed	`NCT01715415` - A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults	Phase 3
Completed	`NCT01716585` - A Study to Evaluate Chronic Hepatitis C Infection	Phase 3
Completed	`NCT02065999` - Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
Completed	`NCT01453075` - Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)	Phase 1
Completed	`NCT01011166` - Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)	Phase 2
Completed	`NCT00557583` - Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults	Phase 1
Terminated	`NCT01586325` - A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients	Phase 1
Recruiting	`NCT02578693` - Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
Recruiting	`NCT02583685` - Switching Regimen in Treating Cirrhotic HCV GT1b Subjects	Phase 2
Completed	`NCT02576314` - Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients	Phase 3
Completed	`NCT01055821` - Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients	Phase 2
Completed	`NCT01833533` - A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection	Phase 3
Completed	`NCT01854697` - A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before	Phase 3